Logo image of JNJ

JOHNSON & JOHNSON (JNJ) Stock Price, Quote, News and Overview

NYSE:JNJ - New York Stock Exchange, Inc. - US4781601046 - Common Stock - Currency: USD

146.82  +0.18 (+0.12%)

After market: 146.99 +0.17 (+0.12%)

JNJ Quote, Performance and Key Statistics

JOHNSON & JOHNSON

NYSE:JNJ (1/24/2025, 8:04:00 PM)

After market: 146.99 +0.17 (+0.12%)

146.82

+0.18 (+0.12%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High168.85
52 Week Low140.68
Market Cap353.49B
Shares2.41B
Float2.41B
Yearly Dividend4.46
Dividend Yield3.38%
PE14.7
Fwd PE13.73
Earnings (Next)N/A N/A
IPO09-25 1944-09-25


JNJ short term performance overview.The bars show the price performance of JNJ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 -4 -6 -8

JNJ long term performance overview.The bars show the price performance of JNJ in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10

The current stock price of JNJ is 146.82 USD. In the past month the price increased by 1.07%. In the past year, price decreased by -7.95%.

JOHNSON & JOHNSON / JNJ Daily stock chart

JNJ Latest News, Press Releases and Analysis

News Image
5 days ago - Chartmill

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.

Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

News Image
2 days ago - MarketBeat

Why Traders Are Buying the Dip on Johnson & Johnson Stock

Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here.

News Image
3 days ago - MarketBeat

Abbott Laboratories Will Outperform Healthcare Stocks in 2025

Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.

News Image
3 days ago - The Motley Fool

5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025

Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).

JNJ Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 77.23 745.61B
NVO NOVO-NORDISK A/S-SPONS ADR 29.42 390.70B
MRK MERCK & CO. INC. 16.06 241.71B
AZN ASTRAZENECA PLC-SPONS ADR 18.13 214.16B
NVS NOVARTIS AG-SPONSORED ADR 13.4 199.87B
PFE PFIZER INC 10.11 147.85B
SNY SANOFI-ADR 12.5 131.58B
BMY BRISTOL-MYERS SQUIBB CO 51 121.02B
ZTS ZOETIS INC 29.27 76.07B
GSK GSK PLC-SPON ADR 8.28 69.92B
TAK TAKEDA PHARMACEUTIC-SP ADR 21.65 41.18B
TEVA TEVA PHARMACEUTICAL-SP ADR 7.8 24.56B

About JNJ

Company Profile

JNJ logo image Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 131,900 full-time employees. The firm's primary focus is products related to human health and well-being. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

Company Info

JOHNSON & JOHNSON

One Johnson & Johnson Plaza

New Brunswick NEW JERSEY 08933 US

CEO: A. Gorsky

Employees: 131900

Company Website: https://www.jnj.com/

Investor Relations: https://www.investor.jnj.com

Phone: 17325242455

JNJ FAQ

What is the stock price of JNJ?

The current stock price of JNJ is 146.82 USD.


What is the symbol for JOHNSON & JOHNSON stock?

The exchange symbol of JOHNSON & JOHNSON is JNJ and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is JNJ stock listed?

JNJ stock is listed on the New York Stock Exchange, Inc. exchange.


Is JNJ a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for JNJ, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of JNJ.


Does JNJ stock pay dividends?

JNJ has a dividend yield of 3.38%. The yearly dividend amount is currently 4.46.


What is the Price/Earnings (PE) ratio of JNJ?

The PE ratio for JNJ is 14.7. This is based on the reported non-GAAP earnings per share of 9.99 and the current share price of 146.82 USD.


What is the Short Interest ratio of JNJ stock?

The outstanding short interest for JNJ is 0.68% of its float.


JNJ Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to JNJ. When comparing the yearly performance of all stocks, JNJ is a bad performer in the overall market: 78.16% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

JNJ Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to JNJ. JNJ has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

JNJ Financial Highlights

Over the last trailing twelve months JNJ reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS increased by -4.22% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.74%
ROA 8.24%
ROE 20.93%
Debt/Equity 0.47
Chartmill High Growth Momentum
EPS Q2Q%-10.92%
Sales Q2Q%5.26%
EPS 1Y (TTM)-4.22%
Revenue 1Y (TTM)4.3%

JNJ Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to JNJ. The Buy consensus is the average rating of analysts ratings from 30 analysts.

For the next year, analysts expect an EPS growth of 7.04% and a revenue growth 2.48% for JNJ


Ownership
Inst Owners72.88%
Ins Owners0.04%
Short Float %0.68%
Short Ratio2.04
Analysts
Analysts74.67
Price Target179.2 (22.05%)
EPS Next Y7.04%
Revenue Next Year2.48%